Endo International +4% after seeing Q1 revenue in-line with estimates

|About: Endo International plc (ENDP)|By:, SA News Editor

Endo International (ENDP +4.2%) jumps 4% after pre-announcing Q1 results with revenue in-line with estimates.

ENDP sees Q1 adjusted EBITDA of $440M-$460M, with revenues rising 5%-7% to $1.015B-$1.035B vs. $964M in the prior-year quarter and $1.02B analyst consensus; results include a $45M impairment for serelaxin after the drug's Phase 3 disappointment.

ENDP also reiterates that it is assessing strategic alternatives for its Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable business.